Form 4 for KNSA Kiniksa Pharmaceuticals International, plc
Accepted 2024-04-03 00:00:00 ET · period of report 2024-04-01 · accession 0001415889-24-010079 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-04-03 | 2024-04-01 | KNSA | Moat Ross | Chief COMMERCIAL Off | M - OptEx | — | +1,612 | 16.0K | +11% | — |
| D | 2024-04-03 | 2024-04-01 | KNSA | Moat Ross | Chief COMMERCIAL Off | F - Tax | $19.70 | -880 | 15.2K | -5% | -$17.3K |
| D | 2024-04-03 | 2024-04-01 | KNSA | Moat Ross | Chief COMMERCIAL Off | M - OptEx | $0.00 | -1,612 | 4,833 | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Share | 2024-04-01 | M | A | 1,612 | — | 16,032 | D | — | — | (F1) Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. |
| 2 | Common | Class A Common Share | 2024-04-01 | F | D | 880 | $19.70 | 15,152 | D | — | — | |
| 3 | Derivative | Restricted Share Unit | 2024-04-01 | M | D | 1,612 | $0.00 | 4,833 | D | — · — to — | 1,612 Class A Common Share | (F1) Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. (F2) The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, April 1, 2023. |